Tenofovir Disoproxil Fumarate

CHEMBL1486 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
635.5 g/mol
LogP
Phase
4

Tenofovir disoproxil fumarate (TDF) is the fumarate salt form of tenofovir disoproxil, an NRTI prodrug that forms the backbone of many HIV-1 antiretroviral regimens and is also approved for chronic hepatitis B treatment. See tenofovir-disoproxil for complete pharmacological details. It is also used for HIV pre-exposure prophylaxis (PrEP) and has been extensively studied in cardiovascular and chronic kidney disease contexts due to its renal effects.

Berat Molekul

635,5000 g/mol

TPSA

260,00 Ų

Area Terapeutik

Mekanisme Kerja

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O

InChI

InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1

Molecular Formula

C23H34N5O14P

HBD / HBA

3 / 18

Ikatan yang Dapat Dirotasi

19

Atom Berat

43

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Tenofovir disoproxil fumarate (TDF) is the fumarate salt form of tenofovir disoproxil, an NRTI prodrug that forms the backbone of many HIV-1 antiretroviral regimens and is also approved for chronic hepatitis B treatment. See tenofovir-disoproxil for complete pharmacological details. It is also used for HIV pre-exposure prophylaxis (PrEP) and has been extensively studied in cardiovascular and chronic kidney disease contexts due to its renal effects.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Tenofovir Disoproxil Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1486. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6398764. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.